Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
•
Endocrinology
Would you prescribe semaglutide for weight gain from androgen deprivation therapy for prostate cancer?
Related Questions
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?
Is there any way to safely treat patients with mCRPC with 177-Lu PSMA who are on hemodialysis?
How do you reconcile discordant PSMA and MRI findings in patients undergoing definitive radiotherapy for prostate cancer?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
Which patients, if any, do you offer transdermal estradiol as a method of ADT instead of LHRH agonists?
Do you offer prostate RT to men with 0-3 bone metastases on conventional imaging when PSMA PET shows a very high number of M1 lesions?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
